"Maximum Tolerated Dose" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
| Descriptor ID |
D020714
|
| MeSH Number(s) |
E05.940.481 G07.690.936.625
|
| Concept/Terms |
Maximum Tolerated Dose- Maximum Tolerated Dose
- Dose, Maximum Tolerated
- Doses, Maximum Tolerated
- Maximum Tolerated Doses
- Tolerated Dose, Maximum
- Tolerated Doses, Maximum
- Maximally Tolerated Dose
- Dose, Maximally Tolerated
- Doses, Maximally Tolerated
- Maximally Tolerated Doses
- Tolerated Dose, Maximally
- Tolerated Doses, Maximally
- Maximal Tolerated Dose
- Dose, Maximal Tolerated
- Doses, Maximal Tolerated
- Maximal Tolerated Doses
- Tolerated Dose, Maximal
- Tolerated Doses, Maximal
|
Below are MeSH descriptors whose meaning is more general than "Maximum Tolerated Dose".
Below are MeSH descriptors whose meaning is more specific than "Maximum Tolerated Dose".
This graph shows the total number of publications written about "Maximum Tolerated Dose" by people in this website by year, and whether "Maximum Tolerated Dose" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 12 | 12 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 10 | 10 |
| 2011 | 0 | 5 | 5 |
| 2012 | 0 | 6 | 6 |
| 2013 | 0 | 7 | 7 |
| 2014 | 0 | 6 | 6 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 6 | 6 |
| 2019 | 0 | 5 | 5 |
| 2020 | 1 | 7 | 8 |
| 2021 | 0 | 4 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 6 | 7 |
| 2025 | 0 | 5 | 5 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Maximum Tolerated Dose" by people in Profiles.
-
Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG. Clin Cancer Res. 2026 Oct 01; 32(19):4307-4318.
-
FcRH5?CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. Nat Med. 2026 Aug; 32(8):2909-2917.
-
L-citrulline treatment of nitric oxide deficiency in MELAS a phase I dose-finding and safety study. Mol Genet Metab. 2026 Sep-Oct; 149(1-2):110209.
-
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors. Cancer Res Commun. 2025 11 01; 5(11):2066-2078.
-
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. Cancer Res Commun. 2025 09 01; 5(9):1574-1583.
-
Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. Clin Cancer Res. 2025 May 01; 31(9):1587-1595.
-
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature. 2025 01; 637(8046):708-715.
-
A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. Cancer Med. 2024 Nov; 13(21):e70376.
-
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. Leuk Lymphoma. 2024 12; 65(12):1789-1800.